A new study published in Stroke journal shows that GLP-1 receptor agonists commonly used for diabetes may significantly lower the risk of nontraumatic brain bleeding (Intracerebral hemorrhage) in people with type 2 diabetes. The drugs also reduced overall stroke and death risk, suggesting broader brain-protective benefits beyond blood sugar control.